Novo Nordisk's ZEUS Setback Deepens a Bruising Stretch for the Danish Drugmaker
Published on 08/01/2026 at 04:51 | Redaktion boerse-global.de
The numbers tell a painful story: a drug that did exactly what it was designed to do biologically, yet delivered zero clinical benefit to patients. For Novo Nordisk, that paradox has now translated into one of its worst trading sessions in recent memory.
Shares in the Danish pharmaceutical giant tumbled 8.48% on Friday to EUR 40.90, with some data points showing the decline as steep as 8.79% to EUR 40.74, after the company unveiled disappointing results from its Phase 3 ZEUS trial. The study, which enrolled more than 6,300 patients suffering from atherosclerosis, chronic kidney disease, and elevated inflammation markers, tested whether Ziltivekimab — an IL-6 inhibitor — could reduce the incidence of major adverse cardiovascular events.
It could not. The drug reliably suppressed inflammatory biomarkers including hsCRP and free IL-6, but the hazard ratio for cardiovascular death, heart attack, and stroke came in at 0.99 — statistically indistinguishable from placebo. In essence, a textbook demonstration that lowering a biomarker does not automatically translate into improved patient outcomes.
Martin Holst Lange, Novo Nordisk's head of research, described the results as disappointing, though the company has stopped short of abandoning its cardiovascular ambitions. Two additional Phase 3 programs with Ziltivekimab — HERMES, targeting heart failure, and ARTEMIS, studying patients following an acute myocardial infarction — remain on track, with data expected in the first half of 2027.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A Non-Cash Hit, But Guidance Holds
The financial fallout from the ZEUS failure will arrive in the third quarter of 2026 in the form of a non-cash impairment charge tied to the program. Crucially, management has reaffirmed its full-year profit guidance, insisting the operational outlook remains intact.
The setback lands at an awkward moment for the company, which is also navigating a legal challenge in the United States. On 28 July, US District Judge Robert Kirsch in New Jersey ruled that portions of a shareholder lawsuit against Novo Nordisk can proceed to trial. Plaintiffs allege the company misled investors about study protocols and the tolerability profile of CagriSema, its combination therapy for obesity.
At the heart of the dispute are protocol amendments to the REDEFINE-1 study that allowed patients to self-adjust their doses when experiencing side effects — changes the plaintiffs claim were never disclosed. When Novo Nordisk later reported an average weight loss of 20.4% for CagriSema, the market reacted negatively, with many investors having anticipated a figure closer to 25%. Ambre James-Brown, the company's vice president of global media relations, has dismissed the allegations as unfounded and vowed a vigorous defense.
The Oral Wegovy Question
With the stock now trading barely above its 200-day moving average of EUR 40.35 and roughly a quarter below its 52-week high of EUR 54.86, the technical picture offers little comfort. The relative strength index sits at 41.8, pointing to neutral-to-weak momentum — a sign that buyers have yet to step in with conviction.
All eyes now turn to Wednesday, 5 August, when Novo Nordisk releases its second-quarter and first-half results. The focus will be on the oral formulation of Wegovy, which received European Commission approval on 15 July as the first oral GLP-1 medication for weight management in the European Union. Market observers view 2026 as a transitional year for the company, with US pricing pressure and intensifying competition weighing on the core business.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The earnings call is expected to shed light on international expansion efforts and manufacturing capacity for the company's blockbuster obesity franchise. The ZEUS disappointment, after all, pertains to diversification into cardiovascular territory — the GLP-1 engine powering Ozempic and Wegovy remains untouched by the trial failure.
Whether the operational strength of that core business can offset the clinical setback, however, is the question investors will be asking when the numbers land. The company has also been quietly expanding its share buyback program, committing to repurchase B-shares worth up to DKK 11.2 billion by February 2027 — a signal that management sees value in its own equity even as the pipeline narrative takes a hit.
Ad
Novo Nordisk Stock: New Analysis - 1 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
